## Company Profile

**Industry Sector:** Biotechnology/Pharmaceutical

**Company Overview:** Company is focused on developing a small molecule drug to treat Alzheimer’s Disease. IP owned by company. In vitro and in vivo studies have given favorable results. Company continues to do contract research and products for which it was formed originally.

**Target Market(s):** Alzheimer’s Patients in US and the world.

## Key Value Drivers

**Technology:** Non immune based, natural component small molecule, no immune reactions as observed with antibody therapeutics. Binds and removes toxic ABeta plaques in brain and circulation

**Competitive Advantage:** Ingredients are well tolerated by the recipients

**Plan & Strategy:** Out license the technology for further development and receive royalty based payments downstream. Alternatively, co-develop the product by partnering with a big pharma.

## Management

**Leadership:** Pazhani Sundaram, President, CEO and Director of Research. With proper funding additional executives will be hired as needed.

**Scientific Advisory Board:** is in progress.

## Product Development

**Research and development**

A small molecule drug, has provided promising results to treat Alzheimer’s model mice. The drug upon injection improved memory correlates in mice and reduced levels of Abeta toxic compound that causes the memory loss in AD. Phase 1 and 2 SBIP grants obtained proof of principle. Additional funding will test safety and toxicity which will lead to IND filing. Get additional funding up to 7 million to perform safety and pharmacological assessments, assess long term toxicity in dogs and chimps. Proceed with FDA to file Investigative new drug and get approval for a phase I clinical trial.